Holley Group was incorporated in Hangzhou, China in 1970 on September 28th, mainly involved in the development of medicine, instrument and electrical automation, biomass fuels, new materials, overseas power engineering and international trade, resource-based industries such as agriculture, involved in the investment of smart grid, biomass resources, new materials, new energy vehicles, international engineering and trade, etc. Holley has become a group company with great health industry as the core business and involved in diversified investment.
So far, Holley has employed more than 10,000 employees around the world, with the subsidiaries and branches spread across North America, South-east Asia, Europe and Africa. Under the umbrella of Holley Group, there are three A share listed companies, Kunming Pharmaceuticals (600422 SH), Wuhan Jianmin Pharmaceuticals (600976 SH) and Huazhi Holdings (000607 SZ). We also take a majority stake in A share company Kaichuang International (600097 SH).
Holley owns three “postdoctoral centers”, three national technology centers, four provincial enterprise technology centers, eleven new high-tech enterprises, which is a scientific research team with 1000 personnels.
Holley also has been selected as Chinese top 500 enterprises, the national top 500 enterprise group, Chinese top 500 private enterprises, Chinese top 100 core competence of machinery industry, Chinese top 100 electronic information and the software industry.
Holley is dedicated to becoming a company that is well recognized and respected by employees, shareholders, clients and society. In 2015, the total revenue of group is 159 billion yuan.